Drug Profile

R 5780

Alternative Names: R-5780

Latest Information Update: 13 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rise Therapeutics
Class Antineoplastics; Immunotherapies; Proteins
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase I Cancer

Most Recent Events

01 Aug 2025 Phase-I clinical trials in Cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06398418)
21 Jan 2025 Rise Therapeutics plans a phase I rial for Solid tumours (Combination therapy, Unresectable/Inoperable, Late-stage disease, Second-line therapy or greater) (PO) in March 2025 (NCT06398418)
13 Jan 2025 R 5780 receives FDA Investigational new drug application clearance for Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com